1. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;The New England Journal of Medicine,2005
2. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;The New England Journal of Medicine,2005
3. Trastuzumab containing regimens for early breast cancer;Moja;Cochrane Database of Systematic Reviews (Online),2012
4. HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with her2-positive early breast cancer at 8 years of median follow up;Goldhirsch;Annals of Oncology,2012
5. HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with her2-positive early breast cancer at 8 years of median follow up;Goldhirsch;Cancer Research,2012